רבולייד 50 מג ישראל - עברית - Ministry of Health

רבולייד 50 מג

novartis israel ltd - eltrombopag as olamine - טבליות מצופות פילם - eltrombopag as olamine 50 mg - eltrombopag - eltrombopag - for the treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura (itp) to increase platelet count and reduce or prevent bleeding.

CAPD 17 תמיסה לדיאליזה צפקית ישראל - עברית - Ministry of Health

capd 17 תמיסה לדיאליזה צפקית

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - magnesium chloride 0.1017 g; calcium chloride 0.1838 g; glucose as monohydrate 16.5 g; lactic acid as sodium 3.925 g; sodium chloride 5.786 g - combinations - combinations - for use in patients with end-stage (decompersated )chronic renal failure of any origin which can be treated with peritoneal dealysis.

CAPD 18 תמיסה לדיאליזה צפקית ישראל - עברית - Ministry of Health

capd 18 תמיסה לדיאליזה צפקית

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - sodium chloride 5.786 g; lactic acid as sodium 3.925 g; glucose as monohydrate 46.75 g; calcium chloride 0.1838 g; magnesium chloride 0.1017 g - combinations - combinations - for use in patients with end-stage (decompersated )chronic renal failure of any origin which can be treated with peritoneal dealysis.

CAPD 19 תמיסה לדיאליזה צפקית ישראל - עברית - Ministry of Health

capd 19 תמיסה לדיאליזה צפקית

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - תמיסה לדיאליזה פריטוניאלית - magnesium chloride 0.1017 g; glucose as monohydrate 25 g; calcium chloride 0.1838 g; sodium chloride 5.786 g; lactic acid as sodium 3.925 g - combinations - combinations - for use in patients with end-stage (decompersated )chronic renal failure of any origin which can be treated with peritoneal dealysis.

אטקנד  4 מג ישראל - עברית - Ministry of Health

אטקנד 4 מג

tzamal bio-pharma ltd - candesartan cilexetil - טבליה - candesartan cilexetil 4 mg - candesartan - candesartan - hypertension. treatment of patients with heart failure and impaired left ventricle systolic function ( left ventricular ejection fraction < or = 40 % ) as add-on therapy to ace inhibitors or when ace inhibitors are not tolerated.

בקטרובן לעור ישראל - עברית - Ministry of Health

בקטרובן לעור

glaxo smith kline (israel) ltd - mupirocin - משחה - mupirocin 2 %w/w - mupirocin - mupirocin - acute primary bacterial skin infections susceptible to the drug e.g. impetigo and folliculitis.

מינס ישראל - עברית - Ministry of Health

מינס

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליות מצופות פילם - ethinylestradiol 0.015 mg; gestodene 0.06 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

נוברינג ישראל - עברית - Ministry of Health

נוברינג

organon pharma israel ltd., israel - ethinylestradiol; etonogestrel - טבעת וגינלית - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - ethinylestradiol - ethinylestradiol - contraception. the safety and efficacy has been established in women aged 18 to 40 years.

נובופם ישראל - עברית - Ministry of Health

נובופם

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - טבליות מצופות פילם - estradiol as hemihydrate 1 mg; norethisterone acetate 1 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis.

סומאברט 10 מג ישראל - עברית - Ministry of Health

סומאברט 10 מג

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 10 mg - pegvisomant - pegvisomant - treatment of patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize igf-i concentrations or was not tolerated.